Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.

Journal:

Circulation

Published:

2025-11-11

DOI:

10.1161/circulationaha.125.077304

Affiliations:

14

Authors:

15

Go to article

Institutions	Authors	Share
Novo Nordisk, Denmark	3.000000	0.20
Novo Nordisk Inc., United States of America (USA)	2.000000	0.13
UCL, United Kingdom (UK)	1.000000	0.07
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	1.000000	0.07
The University of Chicago Medicine, United States of America (USA)	1.000000	0.07
Northwestern University (NU), United States of America (USA)	1.000000	0.07
Novo Nordisk India, India	1.000000	0.07
Stanford University, United States of America (USA)	1.000000	0.07
Mayo Clinic, United States of America (USA)	1.000000	0.07
Kumamoto University, Japan	1.000000	0.07
Hospital Universitario Puerta de Hierro Majadahonda, UAM, Spain	0.500000	0.03
Biomedical Research Networking Centers (CIBER), Spain	0.500000	0.03
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	0.500000	0.03
New York-Presbyterian Hospital, United States of America (USA)	0.500000	0.03

Interested in Clinical Sciences?